174 related articles for article (PubMed ID: 23272809)
1. Pharmacokinetic and pharmacodynamic characterization of a new formulation containing synergistic proportions of interferons alpha-2b and gamma (HeberPAG) in patients with mycosis fungoides: an open-label trial.
García-Vega Y; García-García I; Collazo-Caballero SE; Santely-Pravia EE; Cruz-Ramírez A; Tuero-Iglesias AD; Alfonso-Alvarado C; Cabrera-Placeres M; Castro-Basart N; Duncan-Roberts Y; Carballo-Treto TI; Soto-Matos J; Izquierdo-Toledo Y; Vázquez-Blomquist D; García-Iglesias E; Bello-Rivero I
BMC Pharmacol Toxicol; 2012 Dec; 13():20. PubMed ID: 23272809
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic and pharmacodynamic characterization of a novel formulation containing co-formulated interferons alpha-2b and gamma in healthy male volunteers.
García-García I; Hernández-González I; Díaz-Machado A; González-Delgado CA; Pérez-Rodríguez S; García-Vega Y; Campos-Mojena R; Tuero-Iglesias ÁD; Valenzuela-Silva CM; Cruz-Ramírez A; Martín-Trujillo A; Santana-Milián H; López-Saura PA; Bello-Rivero I;
BMC Pharmacol Toxicol; 2016 Dec; 17(1):58. PubMed ID: 27923408
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic and pharmacodynamic comparison of two "pegylated" interferon alpha-2 formulations in healthy male volunteers: a randomized, crossover, double-blind study.
García-García I; González-Delgado CA; Valenzuela-Silva CM; Díaz-Machado A; Cruz-Díaz M; Nodarse-Cuní H; Pérez-Pérez O; Bermúdez-Badell CH; Ferrero-Bibilonia J; Páez-Meireles R; Bello-Rivero I; Castro-Odio FR; López-Saura PA;
BMC Pharmacol; 2010 Nov; 10():15. PubMed ID: 21092287
[TBL] [Abstract][Full Text] [Related]
4. Bioequivalence of two recombinant interferon alpha-2b liquid formulations in healthy male volunteers.
Garcia-Garcia I; Gonzalez-Delgado CA; Valenzuela-Silva C; Hernandez-Bernal F; Ferrero-Bibilonia J; Soto-Hernandez R; Cervantes-Llano M; Ducongé J; Correa-Fernandez A; Olivera-Ruano L; Lopez-Saura P
Drugs R D; 2004; 5(5):271-80. PubMed ID: 15357626
[TBL] [Abstract][Full Text] [Related]
5. Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions.
Khakoo S; Glue P; Grellier L; Wells B; Bell A; Dash C; Murray-Lyon I; Lypnyj D; Flannery B; Walters K; Dusheiko GM
Br J Clin Pharmacol; 1998 Dec; 46(6):563-70. PubMed ID: 9862245
[TBL] [Abstract][Full Text] [Related]
6. A pharmacokinetic and pharmacodynamic comparison of a novel pegylated recombinant consensus interferon-α variant with peginterferon-α-2a in healthy subjects.
Zheng L; Li MP; Gou ZP; Wang Y; Xu N; Cai YM; Luo H
Br J Clin Pharmacol; 2015 Apr; 79(4):650-9. PubMed ID: 25297637
[TBL] [Abstract][Full Text] [Related]
7. Tumor-associated M2 macrophages in mycosis fungoides acquire immunomodulatory function by interferon alpha and interferon gamma.
Furudate S; Fujimura T; Kakizaki A; Hidaka T; Asano M; Aiba S
J Dermatol Sci; 2016 Sep; 83(3):182-9. PubMed ID: 27342040
[TBL] [Abstract][Full Text] [Related]
8. Biological and clinical effects of the combination of beta- and gamma-interferons administered as a 5-day continuous infusion.
Schiller JH; Storer B; Witt PL; Nelson B; Brown RR; Horisberger M; Grossberg S; Borden EC
Cancer Res; 1990 Aug; 50(15):4588-94. PubMed ID: 2114942
[TBL] [Abstract][Full Text] [Related]
9. Clinical Trial of High-Dose Pegylated-Interferon-Alfa-2b Combined With Phototherapy in Advanced Stage Mycosis Fungoides.
Walker CJ; Espinosa ML; Mehta-Shah N; Pro B; Guitart J; Kuzel T
J Drugs Dermatol; 2021 Mar; 20(3):349-350. PubMed ID: 33683074
[TBL] [Abstract][Full Text] [Related]
10. The Use of Interferons in the Treatment of Cutaneous T-Cell Lymphoma.
Spaccarelli N; Rook AH
Dermatol Clin; 2015 Oct; 33(4):731-45. PubMed ID: 26433845
[TBL] [Abstract][Full Text] [Related]
11. Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia.
Talpaz M; Rakhit A; Rittweger K; O'Brien S; Cortes J; Fettner S; Hooftman L; Kantarjian H
Clin Cancer Res; 2005 Sep; 11(17):6247-55. PubMed ID: 16144928
[TBL] [Abstract][Full Text] [Related]
12. [Folliculotropic mycosis fungoides].
Baratli J; Balakirski G; Megahed M
Hautarzt; 2014 Dec; 65(12):1011-3. PubMed ID: 25355498
[TBL] [Abstract][Full Text] [Related]
13. Intramuscular low dose alpha-2B interferon and etretinate for treatment of mycosis fungoides.
Altomare GF; Capella GL; Pigatto PD; Finzi AF
Int J Dermatol; 1993 Feb; 32(2):138-41. PubMed ID: 8440560
[TBL] [Abstract][Full Text] [Related]
14. Novel long-acting ropeginterferon alfa-2b: Pharmacokinetics, pharmacodynamics and safety in a phase I clinical trial.
Huang YW; Qin A; Fang J; Wang TF; Tsai CW; Lin KC; Teng CL; Larouche R
Br J Clin Pharmacol; 2022 May; 88(5):2396-2407. PubMed ID: 34907578
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma.
Motzer RJ; Rakhit A; Ginsberg M; Rittweger K; Vuky J; Yu R; Fettner S; Hooftman L
J Clin Oncol; 2001 Mar; 19(5):1312-9. PubMed ID: 11230473
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics comparison of two pegylated interferon alfa formulations in healthy volunteers.
Costa MB; Picon PD; Sander GB; Cuni HN; Silva CV; Meireles RP; Góes ACMA; Batoreu NM; Maia MLS; Albuquerque EM; Matos DCS; Saura PL
BMC Pharmacol Toxicol; 2018 Jan; 19(1):1. PubMed ID: 29301580
[TBL] [Abstract][Full Text] [Related]
17. Novel controlled-release Lemna-derived IFN-alpha2b (Locteron): pharmacokinetics, pharmacodynamics, and tolerability in a phase I clinical trial.
De Leede LG; Humphries JE; Bechet AC; Van Hoogdalem EJ; Verrijk R; Spencer DG
J Interferon Cytokine Res; 2008 Feb; 28(2):113-22. PubMed ID: 18279106
[TBL] [Abstract][Full Text] [Related]
18. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group.
Glue P; Fang JW; Rouzier-Panis R; Raffanel C; Sabo R; Gupta SK; Salfi M; Jacobs S
Clin Pharmacol Ther; 2000 Nov; 68(5):556-67. PubMed ID: 11103758
[TBL] [Abstract][Full Text] [Related]
19. Transgenic avian-derived recombinant human interferon-alpha2b (AVI-005) in healthy subjects: an open-label, single-dose, controlled study.
Patel TB; Pequignot E; Parker SH; Leavitt MC; Greenberg HE; Kraft WK
Int J Clin Pharmacol Ther; 2007 Mar; 45(3):161-8. PubMed ID: 17416111
[TBL] [Abstract][Full Text] [Related]
20. Interferon-alpha-associated development of bullous lesions in mycosis fungoides.
Pföhler C; Ugurel S; Seiter S; Wagner A; Tilgen W; Reinhold U
Dermatology; 2000; 200(1):51-3. PubMed ID: 10681616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]